Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma.
To establish serum microRNA profiles as prognostic biomarkers in hepatocellular carcinoma patients (HCCs), we used deep sequencing to screen serum microRNAs in a discovery set .Twelve up-regulated serum miRNAs were selected for qPCR analysis in a training set. MiR-192-5p and miR-29a-3p were identified and associated with HCC prognosis. HCCs with high concentrations of miR-192-5p and miR-29a-3p had poorer overall survival (OS) and progression-free survival (PFS) than those with low concentrations. We calculated a prognostic index (PI) score and classified patients into low-, medium- and high-risk groups. OS and PFS among the 3 groups from the training set were significantly different (all P < 0.05). PI (PIOS, PIPFS) score was the only independent prognostic predictor for OS and PFS of HCCs in the training set. These results were further confirmed in a validation set. In conclusion, differentially expressed serum miRNAs can be helpful for predicting survival in HCCs.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Hao-Tu
HT
Zhu
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Abdulbaqi M E
AM
Hasan
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Rong-Bin
RB
Liu
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zi-Chen
ZC
Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Xiao
X
Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Jing
J
Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Hai-Yun
HY
Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Fang
F
Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, and Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Jian-Yong
JY
Shao
D000328:Adult; D000368:Aged; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000401:mortality / Q000821:virology; D018572:Disease-Free Survival; D005260:Female; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood* / Q000401:mortality / Q000821:virology; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012372:ROC Curve; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; C546783:MIRN192 microRNA, human; C532045:MIRN29a microRNA, human; D035683:MicroRNAs
biomarkers; deep sequencing; hepatocellular carcinoma; prognosis; serum microRNA